NASDAQ:IMNM

Immunome Stock Insider Trading

Healthcare > Biotechnology

Buy IMNM

*Your capital is at risk

$19.18

+0.440 (+2.35%)

At Close: Jun 22, 2026

Immunome Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -11.08. In total, the insiders bought 5.83M and sold 831.19K IMNM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-11.08
● Buy	5.83M shares
● Sell	831.19K shares
83% Buy Activity Strong Negative Correlation
Sell Signal Medium Confidence Jun 15, 2026 Analysis Breakdown: Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 15, 2026 Buy	Stock Option (right to buy) M-Exempt	Rosett Max Chief Financial Officer	C-Suite Officer	60 000 Value: $63.0K
Jun 15, 2026 Sell	Common Stock S-Sale	Rosett Max Chief Financial Officer	C-Suite Officer	60 000 Value: $1.09M
Jun 15, 2026 Buy	Common Stock M-Exempt	Rosett Max Chief Financial Officer	C-Suite Officer	60 000 Value: $63.0K
Jun 10, 2026 Buy	Director Stock Option (right to buy)` A-Award	Swain Sandra M Director	Director	9 897 Value: $179.7K
Jun 10, 2026 Buy	Director Stock Option (right to buy) A-Award	Wagenheim Philip Director	Director	9 897 Value: $179.7K
Jun 10, 2026 Buy	Director Stock Option (right to buy) A-Award	Bienaime Jean Jacques Director	Director	9 897 Value: $179.7K
Jun 10, 2026 Buy	Director Stock Option (right to buy) A-Award	Boylan James P Director	Director	9 897 Value: $179.7K
Jun 10, 2026 Buy	Director Stock Option (right to buy) A-Award	Barchas Isaac Director	Director	9 897 Value: $179.7K
Jun 10, 2026 Buy	Director Stock Option (right to buy) A-Award	Schafer Carol Director	Director	9 897 Value: $179.7K
Jun 05, 2026 Sell	Common Stock S-Sale	Bienaime Jean Jacques Director	Director	10 000 Value: $194.1K
Jun 05, 2026 Buy	Common Stock P-Purchase	Bienaime Jean Jacques Director	Director	6 000 Value: $116.9K
Jun 05, 2026 Buy	Common Stock P-Purchase	Bienaime Jean Jacques Director	Director	3 500 Value: $68.1K
Jun 05, 2026 Sell	Common Stock S-Sale	Bienaime Jean Jacques Director	Director	500 Value: $10K
Jun 05, 2026 Buy	Common Stock P-Purchase	Bienaime Jean Jacques Director	Director	1 000 Value: $19.3K
May 15, 2026 Buy	Common Stock P-Purchase	Bienaime Jean Jacques Director	Director	5 000 Value: $103.5K
Apr 02, 2026 Sell	Common Stock S-Sale	Higgins Jack Chief Scientific Officer	Officer	9 438 Value: $204.2K
Apr 02, 2026 Sell	Common Stock S-Sale	Rosett Max Chief Financial Officer	C-Suite Officer	63 656 Value: $1.39M
Apr 02, 2026 Sell	Common Stock S-Sale	Rosett Max Chief Financial Officer	C-Suite Officer	1 344 Value: $30.2K
Apr 02, 2026 Buy	Stock option (right to buy) M-Exempt	Rosett Max Chief Financial Officer	C-Suite Officer	39 713 Value: $53.6K
Apr 02, 2026 Buy	Common Stock M-Exempt	Rosett Max Chief Financial Officer	C-Suite Officer	39 713 Value: $53.6K
Apr 02, 2026 Buy	Common Stock M-Exempt	Rosett Max Chief Financial Officer	C-Suite Officer	31 848 Value: $33.4K
Apr 02, 2026 Buy	Stock option (right to buy) M-Exempt	Rosett Max Chief Financial Officer	C-Suite Officer	31 848 Value: $33.4K
Mar 30, 2026 Sell	Common Stock G-Gift	Higgins Jack Chief Scientific Officer	Officer	6 291 Value: $0
Mar 27, 2026 Buy	Common Stock P-Purchase	Siegall Clay B President And CEO	CEO / President	25 450 Value: $500.6K
Mar 23, 2026 Sell	Common Stock S-Sale	Wagenheim Philip Director	Director	28 200 Value: $582.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNOME, INC.

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 a...

Read Full Profile Here